Research Site

Newcastle NE7 7DN

1 studies enrolling now · 13 studies all time

What they study most

Acute Coronary Syndrome, Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Advanced Solid Malignancies, Breast Cancer, Clostridioides Difficile Infection, Fracture Healing, Higher-risk Myelodysplastic Syndromes, Migraine Disorders, Other Osteoporosis, Prostate Cancer, Relapsing-Remitting Multiple Sclerosis

Studies at this site

• A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation — Recruiting now
• Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression — Recruiting now
• Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody — Recruiting now
• An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. — Completed
• Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS — Completed
• Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing — Completed
• Study To Assess FRacTure Healing With SclerosTin Antibody - Hip — Completed
• Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) — Stopped early
• Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine — Completed
• Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis — Completed
• ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA) — Completed
• Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis — Completed
• Long Term Open Follow-up With H376/95 vs. Warfarin — Stopped early